From the CEO
Arrowhead CEO Provides Update on Tego Biosciences Corporation
PASADENA, Calif. — Arrowhead Research Corporation’s (NASDAQ: ARWR) Chief Executive Officer announces an update to stockholders on its wholly owned subsidiary, Tego Biosciences Corporation. Dear Arrowhead Stockholders; Since Arrowhead’s inception in 2003, we have followed the development of a relatively new class of molecules, known as fullerenes, with great interest. These are highly ordered clusters of carbon atoms with unique properties that may be leveraged across multiple fields, from industrial uses to medical imaging and therapeutics. In November 2007, we formed Tego Bioscience, Inc. to address these opportunities. Tego, a wholly owned subsidiary of Arrowhead, was created around the acquisition of C Sixty, Inc., a company that had been developing fullerene-based products since 1999. We saw this as a powerful platform because C Sixty was widely recognized as a leader in the new field and the Chairman of its Scientific Advisory Board was Dr. Richard Smalley, who won the 1996 Nobel Prize in Chemistry for his role in discovering fullerenes.
more...Arrowhead CEO Provides Update on Nanotope, Inc.
PASADENA, Calif.— Arrowhead Research Corporation’s (NASDAQ: ARWR) Chief Executive Officer announces an update to stockholders on its minority investment, Nanotope, Inc.. Dear Stockholders: In 2005, Dr. Samuel Stupp, Director of Northwestern University’s Institute for Bionanotechnology in Medicine, and I co-founded Nanotope Inc., a regenerative medicine company. I strongly believed that medicine would be forever transformed if we could move beyond simply replacing failed body parts and shift the industry toward a less invasive method of regenerating damaged tissues. This would represent no less than a paradigm shift in healthcare, but, of course, identifying an opportunity is simple; the difficult challenge is to develop and scale an appropriate technology platform. Dr. Stupp had been working toward this vision and his work was well positioned to be the technology basis of a new regenerative medicine company.
more...Arrowhead CEO Provides Update on Majority Owned Subsidiary Unidym, Inc.
PASADENA, Calif.—Arrowhead Research Corporation’s (NASDAQ: ARWR) Chief Executive Officer announces an update to stockholders on its majority owned subsidiary, Unidym: Dear Stockholders: Unidym is Arrowhead’s most developed nanomaterials company and a premier example of our model for building new technology companies. As with Calando, we believe Unidym is a demonstration of our ability to build potentially transformational companies that have near-term market entry points. Unidym is a platform company positioned to address sizeable long-term product opportunities in the electronics industry and, more importantly in the current market environment, significant short-term opportunities in the high growth touch panel and display industries.
more...Arrowhead CEO Provides Update on Wholly Owned Subsidiary Agonn Systems, Inc.
PASADENA, Calif. — Arrowhead Research Corporation’s (NASDAQ: ARWR) Chief Executive Officer announces an update to stockholders on its wholly owned subsidiary, Agonn Systems Corporation: Dear Arrowhead Stockholders, Agonn Systems Corporation, Arrowhead’s newest subsidiary, seeks to leverage Arrowhead’s expertise in carbon nanotechnology to improve energy storage products. Consistent with our conservative strategy in the current market environment, Agonn is currently pursuing a capital efficient R&D model based on outsourced prototyping and testing in partnership with its key technical consultants at Georgia Tech, MIT, University of Pittsburgh, and University of Dayton.
more...Arrowhead CEO Provides Update on Majority Owned Subsidiary Calando Pharmaceuticals Inc.
PASADENA, Calif.—Arrowhead Research Corporation (NASDAQ: ARWR) announced today that the Company's CEO has provided an update letter to stockholders on its majority owned subsidiary, Calando Pharmaceuticals: Dear Arrowhead Stockholders, Calando Pharmaceuticals is Arrowhead’s most mature biopharmaceutical subsidiary. Based on technology developed at the California Institute of Technology, Calando’s proprietary linear cyclodextrin nanoparticle technology has been optimized to deliver small molecule drugs using Calando’s CyclosertTM system and RNAi therapeutics using the RONDELTM system. Using these platform systems, Calando has developed two anti-cancer drug candidates that are currently undergoing human clinical trials.
more...Arrowhead CEO Updates Stockholders
Pasadena, California — Arrowhead Research Corporation (NASDAQ: ARWR) announced today that the Company's CEO has provided an update letter to stockholders: Dear Arrowhead Stockholders, In order to provide an update on Arrowhead’s operational and strategic initiatives, I plan to release seven weekly newsletters. This first edition focuses on Arrowhead’s overall strategy and provides a broad overview of its subsidiaries. Every week over the next six weeks, Arrowhead will release a focused newsletter on each of its four majority-owned subsidiaries: Unidym Inc., Calando Pharmaceuticals Inc., Agonn Systems Corporation and Tego Biosciences Corporation. This and future newsletters will also review developments at Nanotope Inc. and Leonardo Biosystems, Inc., both entities in which Arrowhead currently holds a minority interest. We intend to increase our equity position in these two companies over time to achieve majority ownership.
more...